Search Results
Your search for ,WhO matches 21072 pages
Showing 2101 - 2150From a Small Town in Lebanon, a Young Doctor Follows His Passion to an International Career in Cancer Research
Philip A. Salem, MD, Director Emeritus of Cancer Research at St. Luke’s Episcopal Hospital, Houston, was born and reared in Bterram, a village that overlooks the Mediterranean Sea. “I had the most beautiful and blessed childhood, as I lived in a household dominated by a father who believed in the...
ACS and Flatiron Health Announce Recipients of Fourth Annual Real-World Data Impact Awards
The American Cancer Society (ACS) and Flatiron Health announced the recipients of the 2023 Real-World Data Impact Awards, which will support clinically relevant research regarding the treatment of and outcomes for patients with cancer. 2023 marks the fourth year of the joint grant-making program,...
Neoadjuvant Therapy for EGFR-Positive Lung Adenocarcinoma
This is Part 3 of Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Melissa Johnson, Vamsidhar Velcheti, and Helena Yu discuss the neoadjuvant treatment ...
Management of Stage IIIA NSCLC in a Former Smoker
This is Part 2 of Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Melissa Johnson, Vamsidhar Velcheti, and Helena Yu discuss the management of stage...
Locally Advanced NSCLC
This is Part 1 of Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Melissa Johnson, Vamsidhar Velcheti, and Helena Yu discuss the management of locally ...
Metastatic Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Single-Agent Chemotherapy in Previously Treated Patients
As reported in the Journal of Clinical Oncology by Aditya Bardia, MD, MPH, and colleagues, final results of the phase III ASCENT trial showed continued superior progression-free and overall survival with sacituzumab govitecan-hziy, an anti–trophoblast cell surface antigen 2 (Trop-2) antibody-drug...
Risk Score to Assess Cardiovascular Complications in Hematopoietic Stem Cell Transplant Recipients
A novel tool may help predict the risk of complications following hematopoietic stem cell transplantation and guide the pretransplant process, according to new Scientific Statement published by Hayek et al in Circulation. The findings may also illuminate the contemporary prevalence of...
Collaborative Care Intervention May Benefit Patients With Cancer, Health-Care Systems
Adding specialized mental health support to the treatment plan of patients with cancer may improve their quality of life, lower the risk of cardiovascular disease in family caregivers, and boost cost savings to the health-care system, according to a recent study published by Steel et al in The...
HPV-Associated Oropharyngeal Cancer: Intratreatment FDG-PET Response as a Biomarker for De-escalation of Radiotherapy
The use of imaging midtreatment for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma may guide the use of deintensified chemoradiotherapy, according to a phase II study from the University of Michigan presented by Regan et al at the 2024 Multidisciplinary Head and Neck...
Zanubrutinib vs Acalabrutinib in Relapsed or Refractory CLL: New Efficacy Analysis
A new matching adjusted indirect comparison of the efficacy of zanubrutinib vs acalabrutinib in relapsed or refractory chronic lymphocytic leukemia (CLL) based on data from the phase III ALPINE and ASCEND trials was presented by Shadman et al at the 28th Annual International Congress on Hematologic ...
Worsening Metabolic Syndrome May Increase Cancer Risk
Investigators may have identified a heightened risk of various types of cancers among patients with persistent and worsening metabolic syndrome, according to a recent study published by Deng et al in Cancer. Background Metabolic syndrome encompasses conditions such as high blood pressure, elevated...
Higher BMI May Be Linked to Complications Following Autologous Breast Reconstruction
Patients with a higher body mass index (BMI) may have a greater risk of overall and specific complications following autologous breast reconstruction, according to a recent study published by Barnes et al in Plastic and Reconstructive Surgery. Background Autologous breast reconstruction—an...
ASCO Chief Medical Officer Testifies to Congress About Ongoing Cancer Drug Shortage Crisis
On February 6, 2024, Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of the Association for Clinical Oncology (ASCO), testified before the full House Committee on Ways and Means on the crisis of ongoing cancer drug shortages. More than 15 cancer drugs continue...
ASCO and SSO Publish New Guideline on Germline Testing in Breast Cancer
ASCO in partnership with the Society of Surgical Oncology (SSO) has released a new guideline addressing recommendations in germline testing in patients with breast cancer.1 The guideline provides oncologists with a framework for how to approach germline testing and recommendations for who should be ...
Expert Point of View: Rachid Baz, MD
DREAMM-7, which evaluated belantamab mafodotin-blmf, bortezomib, and dexamethasone (BVd) in relapsed or refractory multiple myeloma, was discussed at the virtual session by Rachid Baz, MD, Myeloma Section Head and Co-Director of the Pentecost Family Myeloma Research Center at Moffitt Cancer Center, ...
Geriatric Oncology Educational Opportunity at Memorial Sloan Kettering Cancer Center
Once again, geriatric oncology will take the forefront at Memorial Sloan Kettering (MSK). On April 23, 2024, the Division of Advanced Practice Providers and the Geriatric Medicine Service at MSK will host the 3rd annual Geriatric Oncology Symposium for Advanced Practice Providers. The target...
I Am Young and Fit—and Have Stage IV Alveolar Soft-Part Sarcoma
Except for my right thigh being bigger than my left thigh, there was no hint that I was harboring advanced alveolar soft-part sarcoma when I was diagnosed with the cancer in 2019. I initially chocked up the discrepancy in my legs to the vigorous workouts I had received during my cheerleading days,...
Fruquintinib in Refractory Metastatic Colorectal Cancer
On November 8, 2023, fruquintinib (Fruzaqla) was approved for adults with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy; and—if RAS wild-type and medically appropriate—an anti-EGFR therapy.1 Supporting...
How The Max Foundation Is Accelerating Equitable Cancer Care Globally
When Pat Garcia-Gonzalez’ stepson, Max, was diagnosed with chronic myeloid leukemia (CML) in 1988 at the age of 14, the Internet was still in its infancy and decades away from the networking resource it has become today. Told that Max would need an allogeneic stem cell transplant to survive, the...
Olaparib Plus Abiraterone and Prednisone Improves Outcomes Over Single Agents in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
First-line treatment with the PARP inhibitor olaparib plus the androgen biosynthesis inhibitor abiraterone acetate and the steroid prednisone improved progression-free survival and response rates compared with either treatment alone (ie, olaparib or abiraterone plus prednisone) in patients with...
Relationship Between Second Malignant Neoplasm and Heart Disease Studied in Childhood Cancer Survivors
In a French study of more than 7,000 childhood cancer survivors, published in JACC: CardioOncology, Thibaud Charrier, PhD, of the Université Paris-Saclay, Villejuif, France, and colleagues reported that the occurrence of a second malignant neoplasm among these childhood cancer survivors seemed to...
Newly Diagnosed Multiple Myeloma
“Ask yourself at every moment, ‘Is this necessary?’” —Marcus Aurelius To complement The ASCO Post’s extensive coverage of the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, here are two important abstracts selected from the meeting proceedings focusing on induction and...
Long-Term Follow-up Affirms Benefit of Pembrolizumab Plus Chemotherapy in Advanced Esophageal Cancer
Long-term follow-up of the phase III KEYNOTE-590 trial confirms the benefit of the PD-1 inhibitor pembrolizumab plus chemotherapy in advanced esophageal cancer. As compared with chemotherapy alone, after a median of follow-up of almost 59 months, patients treated with the chemoimmunotherapy...
Expert Point of View: Michael Crump, MD
Michael Crump, MD, of the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, expressed some concerns about the study presented by Shadman et al in patients with large B-cell lymphoma (LBCL). “These data should be interpreted with caution. The patient...
Should You Reconsider Transplant for Relapsed Large B-Cell Lymphoma in Complete Remission?
For patients with relapsed large B-cell lymphoma (LBCL) in complete remission, outcomes were better after autologous stem cell transplantation (ASCT) than with chimeric antigen receptor (CAR) T-cell therapy in a retrospective analysis of a large database presented at the 2023 American Society of...
Expert Point of View: Aparna R. Parikh, MD
he latest findings for circulating tumor DNA (ctDNA) in colorectal cancer were discussed at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium by Aparna R. Parikh, MD, a gastrointestinal oncologist at Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard...
Studies Show Progress in Using ctDNA to Guide Colorectal Cancer Treatment
Circulating tumor DNA (ctDNA) has become an established biomarker of measurable or molecular residual disease (MRD) after curative-intent surgery in patients with colorectal cancer. The research focus is now on linking ctDNA to long-term outcomes and using it to guide treatment decisions—which was...
Expert Point of View: Alan P. Venook, MD, FASCO
For perspective on CheckMate 8HW, The ASCO Post interviewed Alan P. Venook, MD, FASCO, the Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California San Francisco and the Shorenstein Associate Director for Program Development at the Helen...
Nivolumab Plus Ipilimumab Improves Progression-Free Survival in First-Line Setting of Metastatic Colorectal Cancer
In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) nonresectable or metastatic colorectal cancer derived significant benefit from an immunotherapy doublet, with nivolumab plus ipilimumab reducing the...
Expert Point of View: Pedro Barata, MD, MSc, FACP
Invited discussant of KEYNOTE-564, Pedro Barata, MD, MSc, FACP, of the University Hospital Seidman Cancer Center, Cleveland, said the reasons for the disparate results in these two adjuvant trials of checkpoint inhibitors were likely the result of many factors. “Factors such as histology, different ...
Two Adjuvant Therapy Studies Show Divergent Outcomes With PD-1 Inhibitors in Renal Cell Carcinoma
In the third prespecified interim analysis of the phase III KEYNOTE-564 trial,1 adjuvant treatment with the PD-1 inhibitor pembrolizumab significantly improved overall survival compared with placebo in patients with intermediate- or high-risk clear cell renal cell carcinoma (RCC). However, a...
Novel MDM2 Inhibitor for Salivary Gland Cancers
A novel MDM2 inhibitor, APG-115 (alrizomadlin), has demonstrated antitumor activity and good tolerability in patients with progressive salivary cancer, particularly adenoid cystic carcinoma, according to data presented by Swiecicki et al at the 2024 Multidisciplinary Head and Neck Cancers Symposium ...
Five New Cancer Grand Challenges Teams Named in Global Effort to Resolve Hurdles in Cancer Research
The Cancer Grand Challenges initiative announced it has selected five new global teams that will each receive up to $25 million in funding over the course of 5 years to address four major challenges faced by cancer research. Background In March 2023, the initiative unveiled nine new challenges to...
Inherited Genetic Factors May Influence Risk of Subsequent Cancer Diagnoses in Childhood Cancer Survivors
Investigators have found that common inherited genetic factors capable of predicting cancer risk in the general population may also help to predict childhood cancer survivors who may be at elevated risk of new cancers later in life, according to a recent study published by Gibson et al in Nature...
FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma
On March 7, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the small-molecule BTK inhibitor zanubrutinib (Brukinsa) in combination with the anti-CD20 monoclonal antibody obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more lines of ...
FDA Approves Nivolumab in Combination With Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma
On March 6, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. CheckMate 901 Efficacy was evaluated in CheckMate ...
Topical Diclofenac to Prevent Capecitabine-Associated Hand-Foot Syndrome
In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast or gastrointestinal cancer who were ...
Patients With Early-Stage HR-Positive Breast Cancer May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
Newly published study results revealed that use of the Breast Cancer Index (BCI) test led to physicians changing their long-term antiestrogen treatment recommendations for 40% of patients with early-stage hormone receptor–positive breast cancer. The results, which suggest that many women may be...
Factors Associated With Myeloid Neoplasms Following CAR T-Cell Therapy
In an analysis reported in a research letter in JAMA Oncology, Gurney et al identified factors associated with an increased risk of myeloid neoplasms after chimeric antigen receptor (CAR) T-cell therapy. Study Details Investigators identified adults who received CAR T-cell therapy between June 2016 ...
Low-Risk Cervical Cancer: Pelvic Recurrence With Simple vs Radical Hysterectomy
As reported by Marie Plante, MD, and colleagues in The New England Journal of Medicine, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in terms of pelvic recurrence in women with low-risk cervical cancer. Simple hysterectomy was associated with a reduced...
Could Smoking-Related DNA Changes Reflect Differential Lung Cancer Risks by Race and Ethnicity?
Investigators may have uncovered differential associations between smoking and DNA methylation across various racial and ethnic groups, according to a recent study published by Huang et al in the American Journal of Human Genetics. The findings could lead to the development of new strategies to...
Endocrine-Resistant HR-Positive/HER2-Negative Metastatic Breast Cancer
This is Part 3 of Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Kevin Kalinsky, Manali Bhave, and Ruth O’Regan discuss the treatment of...
HR-Positive/HER2-Negative Metastatic Breast Cancer With PIK3CA Mutation
This is Part 2 of Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Kevin Kalinsky, Manali Bhave, and Ruth O’Regan discuss the treatment of...
HPV-Associated Oropharyngeal Cancer: Adjuvant Treatment Deintensification
Postoperative adjuvant therapy—both chemoradiotherapy and radiotherapy alone—for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma may be safely de-escalated, according to results presented by Thorstad et al at the 2024 Multidisciplinary Head and Neck Cancers Symposium...
NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and Other Cancers
The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The evidence-based expert consensus recommendations are the most frequently updated guidelines for...
Lenvatinib Plus Pembrolizumab Fails to Improve Overall Survival in Recurrent or Metastatic Head and Neck Cancer
Adding the multikinase inhibitor lenvatinib to the PD-1 inhibitor pembrolizumab as initial therapy for recurrent or metastatic head and neck squamous cell carcinoma improved response rates and progression-free survival but did not lead to an overall survival advantage over pembrolizumab...
Can HPV ctDNA Guide the Adjuvant Treatment of Oropharyngeal Cancer?
Although liquid biopsies are now helping determine the need for adjuvant therapy in a number of malignancies, they have yet to prove useful in the setting of oropharyngeal carcinoma, according to a prospective pilot study presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium that...
Racial/Ethnic Differences in Treatment Outcomes Among Patients With Triple-Negative Breast Cancer
In a study reported in the Journal of Clinical Oncology, Woriax et al identified racial/ethnic differences in pathologic complete response rates and overall survival among women with triple-negative breast cancer who received neoadjuvant chemotherapy. Study Details The study involved data from the...
Impact of Behavioral Health Disorders on Cancer Surgery Outcomes
Investigators may have uncovered new insights into the relationship between behavioral health disorders and cancer surgery outcomes, according to a recent study published by Katayama et al in the Journal of the American College of Surgeons. The findings clarified the need for behavioral health...
Circulating Leukocyte Subsets After Breast Cancer Diagnosis and Treatment
In an analysis reported in JAMA Network Open, Jacob K. Kresovich, PhD, and colleagues identified differences in circulating leukocyte subsets between women who were diagnosed and treated for breast cancer vs those not diagnosed with breast cancer. As stated by the investigators: “Changes in...
